Windsor Creek Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Windsor Creek Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-13,763	Closed	-$58K	–	180
2021 Q2	$58K	Hold	13,763	–	–	0.02%	166
2021 Q1	$69K	Hold	13,763	–	–	0.02%	169
2020 Q4	$174K	Hold	13,763	–	–	0.04%	177
2020 Q3	$135K	Hold	13,763	–	–	0.04%	164
2020 Q2	$137K	Buy	13,763 +142	+1%	+$1.36K	0.05%	153
2020 Q1	$120K	Buy	+13,621	New	+$134K	0.04%	155

Other funds holding CNCE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Windsor Creek Advisors's CNCE Position: Q3 2021 in Review

Windsor Creek Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2021, closing a stake of 13,763 shares — an estimated $58K sold.

Windsor Creek Advisors first reported a position in CNCE in Q1 2020 and held it in 6 quarters. The position peaked at $174K in Q4 2020. 61 funds tracked by Wall St. Rank hold CNCE as of Q3 2021.

Windsor Creek Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Windsor Creek Advisors sold 13,763 Concert Pharmaceuticals, Inc. shares in Q3 2021, an estimated $58K.
Windsor Creek Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q1 2020 and held it in 6 quarters.
Windsor Creek Advisors's Concert Pharmaceuticals, Inc. position peaked at $174K in Q4 2020.
61 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2021.

Based on Windsor Creek Advisors's 13F filing for Q3 2021, filed 3 Nov 2021.